U.K. Oncology Companion Diagnostic Market Size & Outlook
- Clinical Diagnostics
- In Vitro Diagnostics
- oncology companion diagnostics market
- In Vitro Diagnostics
Global Market
Related Markets
Ask a question about the oncology companion diagnostics market
UK oncology companion diagnostic market highlights
- The UK oncology companion diagnostic market generated a revenue of USD 182.6 million in 2023 and is expected to reach USD 328.0 million by 2030.
- The UK market is expected to grow at a CAGR of 8.7% from 2024 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2023.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Oncology companion diagnostic market data book summary
| Market revenue in 2023 | USD 182.6 million |
| Market revenue in 2030 | USD 328.0 million |
| Growth rate | 8.7% (CAGR from 2024 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | Agilent Technologies Inc, Illumina Inc, Qiagen NV, Thermo Fisher Scientific Inc, ARUP Laboratories, Abbott Laboratories, Myriad Genetics Inc, BioMerieux SA, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, UK accounted for 3.8% of the global oncology companion diagnostic market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany oncology companion diagnostic market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 497.9 million by 2030.
The advanced healthcare infrastructure, strategic collaborations, and introduction of innovative products are expected to drive market growth in the UK. Government support and initiatives will further bolster the country’s oncology companion diagnostic market over the next decade. Public-private partnerships for CDx are set to accelerate market expansion.
For instance, in July 2024, Danaher inaugurated two new laboratories in the UK and the U.S. to speed up the development and commercialization of companion & complementary diagnostics, thus enhancing the drug development process. The first lab, opening July 2024 in Newcastle, UK, will function as a research hub for academic & pharmaceutical collaborations and is situated at the Leica Biosystems complex, a Danaher subsidiary.
The second lab is in an undisclosed U.S. location. This initiative is expected to strengthen Danaher's market position. Furthermore, government entities like the NHS are implementing measures to promote the use of these tests, making them cost-effective & widely accessible, saving time, and reducing the risk of complications. Such initiatives are expected to boost demand for CDx products and drive market growth.
No credit card required*
Publish Date: Jan 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Companion Diagnostics Market
Oncology Companion Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| ARUP Laboratories | View profile | 1001-5000 | Salt Lake City, Utah, United States, North America | www.aruplab.com |
U.K. oncology companion diagnostics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Oncology Companion Diagnostic Market Outlook will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 66.54% in 2023.
Horizon Databook has segmented the U.K. oncology companion diagnostic market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
The advanced healthcare infrastructure, strategic collaborations, and introduction of innovative products are expected to drive market growth in the UK. Government support and initiatives will further bolster the country’s oncology companion diagnostic market over the next decade. Public-private partnerships for CDx are set to accelerate market expansion.
For instance, in July 2024, Danaher inaugurated two new laboratories in the UK and the U.S. to speed up the development and commercialization of companion & complementary diagnostics, thus enhancing the drug development process. The first lab, opening July 2024 in Newcastle, UK, will function as a research hub for academic & pharmaceutical collaborations and is situated at the Leica Biosystems complex, a Danaher subsidiary.
The second lab is in an undisclosed U.S. location. This initiative is expected to strengthen Danaher's market position. Furthermore, government entities like the NHS are implementing measures to promote the use of these tests, making them cost-effective & widely accessible, saving time, and reducing the risk of complications. Such initiatives are expected to boost demand for CDx products and drive market growth.
- U.K. Oncology Companion Diagnostic Market Product & Service Outlook (Revenue, USD Million , 2018-2030)
- Product
- Service
- U.K. Oncology Companion Diagnostic Market End Use Outlook (Revenue, USD Million , 2018-2030)
- Hospital
- Pathology/Diagnostic laboratory
- Academic medical center
- U.K. Oncology Companion Diagnostic Market Disease Type Outlook (Revenue, USD Million , 2018-2030)
- Breast cancer
- Non-small cell lung cancer
- Colorectal cancer
- Leukemia
- Melanoma
- Prostate cancer
- Others
- U.K. Oncology Companion Diagnostic Market Technology Outlook (Revenue, USD Million , 2018-2030)
- Polymerase chain reaction (PCR)
- Next-generation sequencing (NGS)
- Immunohistochemistry (IHC)
- In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
- Other technologies
Reasons to subscribe to oncology companion diagnostics market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of oncology companion diagnostics market databook
- Our clientele includes a mix of oncology companion diagnostics market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. oncology companion diagnostics market, including forecasts for subscribers. This country databook contains high-level insights into U.K. oncology companion diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.K. Oncology Companion Diagnostic Market, 2018-2030 (US$M)
UK oncology companion diagnostics market statistics, by product & service, 2018-2030 (US$M)
